AUS
NZ
UK
CA
USA
IND
Highlights
- The AI-backed cardiac diagnostic software of Artrya has received a breakthrough in the UK.
- The tender bid in the UK has been successful and now the Company is accepted in the National Health Service Shared Business Services.
- As per the agreement framework, now the firm will be supplying its AI-backed platforms and software in the UK market.
Artrya is a Perth-based Cardiac imaging AI company that will be conducting its IPO on 26 November. Just weeks out from the IPO, the AI-backed cardiac diagnostic software of Artrya (which is at the nationwide trial stage) got a breakthrough in the UK.
The tender bid in the UK has been successful and resulted in the acceptance of the Company in the National Health Service Shared Business Services (NHS SBS). Now, Artrya will be supplying AI platforms and softwares in the UK.
As per the framework agreement, Artrya has been tagged as the pre-qualified, preferred and select in the list of approved suppliers. The services can be commissioned by the 1250 NHS hospital and numerous public organisations as well.
John Barrington, Co-founder and managing director of Artrya stated that it is a significant milestone for the company as it adds value to the European commercialisation plan. He added that,
It has been anticipated by Artrya that by mid-2022, the company will be able to sell in the UK market. In early 2022, the Company is planning for unrestricted launch after getting the approval on technology by the Therapeutic Good Administration (TGA), that is, the technology will be free for licencing and commercialisation across Australia.
The success of Artrya is driven by the importance it gives to privacy, international data, governance standards and clinical validation along with demonstrating the warranty, insurance, safety, unique value and capabilities of the product.
Bottom Line
The Company which was at the nationwide trial phase marks its entry in the UK market. Also, it has been able to add a gem to its plan to commercialise in the European market. It will be interesting to see, how it will affect the company’s IPO.
